1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
668F599E87C2765BE85257487005521F0
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/rituxan-case-study-pre-launch-communications-to-change-the-dominant-treatment-paradigm
18
19
2054.146.206.127
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Sales and Marketing New Product Development and Launch Managing Thought Leader Programs Support and Communication

Rituxan Case Study: Pre-Launch Communications to Change the Dominant Treatment Paradigm

ID: 5006


Features:

Graphics, Detailed Process Map


Pages/Slides: 31


Published: Pre-2013


Delivery Format: Online PDF Document


 

License Options:

close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.

Buy Now

 

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: To download a complimentary excerpt of this study, please click here

STUDY OVERVIEW


This case study reviews the strategy and tactics utilized by Genentech for the Rheumatoid Arthritis (RA) indicated product, Rituxan, to communicate with KOLs regarding a new mechanism of action treatment for moderate-to-severe RA. The company started by using advisory boards early to harvest insights and seed new ideas before turning to communication vehicles such as peer-to-peer discussions and seminars to redefine RA's existing scientific model for the medical community. The approach created understanding and acceptance for Rituxan's new mechanisms of action. Executives and managers can use this study to gain insights into the creation of messages that communicate how a product with a new MOA changes a dominate treatment paradigm.

KEY TOPICS

  • Market Entry Background
  • Seeding New Ideas that Challenge Orthodoxy
  • Early Advisory Boards to Generate Insights and New Ideas
  • Engaging Thought Leaders to Refine Disease State Conceptual Model
  • Pre-Launch Scientific Communications for KOLs
  • Managing Expectations Pre-Launch and Post-Launch
  • Lessons Learned

SAMPLE LESSON LEARNED
  • Critically Examine the Scientific Rationale that Supports or Opposes the New Mechanism-of-Action Medicine.
  • Use Peer-to-Peer Discussions to Extend Science Across the Market.
METHODOLOGY
The data for this case study was collected utilizing primary research via executive interviews and supplemental secondary research.

Industries Profiled:
Biotech; Chemical; Pharmaceutical


Companies Profiled:
Genentech


If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.